Abstract
Peripheral mononuclear blood cells (PBMCs) are the most widely used study materials for immunomonitoring and antigen-specific T-cell identification. However, limited patient PBMCs and low-frequency antigen-specific T cells remain as significant technical challenges. To address these limitations, we established a novel platform comprised of optimized HLA-matched immortalized B cells transfected with mRNA of a prototype viral or tumor antigen conjugated to MHC class-I trafficking domain protein (MITD) to increase the efficiency of epitope expression in antigen-presenting cells (APCs) essential to expanding antigen-specific T cells. When applied to CMV as a model, the IBMAM platform could successfully expand CMV-specific T cells from low-frequency CMV PBMCs from seropositive donors. Additionally, this platform can be applied to the validation of antigen specific TCRs. Together, compared to using APCs with synthesized peptides, this platform is an unlimited, highly efficient, and cost-effective resource in detecting and expanding antigen-specific T cells and validating antigen-specific TCRs.
Original language | English (US) |
---|---|
Article number | 796 |
Journal | Biomedicines |
Volume | 11 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2023 |
Externally published | Yes |
Keywords
- antigen-specific T cells
- B cell immortalization
- CMV
- immunomonitoring
- MITD
- mRNA
- novel platform
- TCR validation and discovery
ASJC Scopus subject areas
- Medicine (miscellaneous)
- General Biochemistry, Genetics and Molecular Biology